QMS Medical Allied Services Limited has confirmed compliance with the Structured Digital Database (SDD) requirements for the financial year ended March 31, 2026. The company submitted the necessary compliance certificate to the National Stock Exchange of India Ltd., certifying that its internal systems for tracking Unpublished Price Sensitive Information (UPSI) are fully operational and secure. This adherence to regulatory standards mitigates the risk of insider trading and ensures transparency in information dissemination.

Regulatory Filing Details

The submission was made pursuant to Regulation 3(5) and 3(6) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. As the provisions of Regulation 24A of SEBI (LODR) Regulations, 2015 are not applicable to the entity, QMS Medical Allied Services was required to file the certificate within 60 days from the end of the financial year. The document was certified by M/s. Maharshi Ganatra & Associates, a Practicing Company Secretary.

Compliance Status

The certificate validates that the company maintains a non-tamperable digital database with controlled access and a comprehensive audit trail. It confirms that all UPSI disseminated during the previous quarter was captured with the necessary details, including the nature of the information and the precise date and time. The system is designed to retain records for a period of 8 years.

Key Certification Points

The certification further clarifies that the company was required to capture one event during the quarter and successfully recorded the said event. No instances of non-compliance were observed in the quarter ended March 31, 2026.

QMS Medical Allied Services Limited has submitted the Monitoring Agency Report for the quarter ended March 31, 2026, to the National Stock Exchange of India. The disclosure was made in compliance with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

CARE Ratings Limited, appointed as the monitoring agency, verified the utilization of proceeds from the company's Rights Issue. The issue size aggregated to ₹12.05 crore, comprising equity shares allotted during the period from September 12, 2025, to September 22, 2025.

The agency confirmed that there was no deviation from the objects of the issue. The funds were primarily allocated for the acquisition of a further 25% stake in a subsidiary, general corporate purposes, and issue expenses. The monitoring agency verified the utilization through bank statements, management certificates, and Chartered Accountant certificates.

Utilization of Proceeds

The company reported that the total amount utilized as of the end of the quarter was ₹12.05 crore. The acquisition of the subsidiary stake and issue expenses were fully utilized, while general corporate purposes saw a utilization of ₹0.01 crore during the quarter for payments to creditors.

General Corporate Purpose Details

The funds allocated for general corporate purposes were utilized for routine business expenditures. The company provided a board resolution dated September 23, 2025, approving the fund utilization for expenses incurred in the ordinary course of business, including payments to creditors and statutory dues.

The monitoring agency noted that the actual allotment of shares was slightly lower than the planned issue size due to SME rights issue norms requiring allotment in specific lot sizes. The revised cost of objects was approved by the board.